CN111826434A - Application of microRNA marker miR-122-5p in hepatic fibrosis diagnosis - Google Patents

Application of microRNA marker miR-122-5p in hepatic fibrosis diagnosis Download PDF

Info

Publication number
CN111826434A
CN111826434A CN202010375751.7A CN202010375751A CN111826434A CN 111826434 A CN111826434 A CN 111826434A CN 202010375751 A CN202010375751 A CN 202010375751A CN 111826434 A CN111826434 A CN 111826434A
Authority
CN
China
Prior art keywords
hepatic fibrosis
microrna
seq
plasma
hepatitis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010375751.7A
Other languages
Chinese (zh)
Inventor
李宁
王宇
张永宏
张才达
米海铭
张跃伟
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Beijing Quantobio Biotechnology Co ltd
Original Assignee
Beijing Quantobio Biotechnology Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Beijing Quantobio Biotechnology Co ltd filed Critical Beijing Quantobio Biotechnology Co ltd
Publication of CN111826434A publication Critical patent/CN111826434A/en
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The invention provides a hepatic fibrosis microRNA marker, namely a microRNA nucleic acid molecule: miR-122-5p and application thereof in preparing hepatic fibrosis diagnosis reagent. The content of the microRNA marker in the plasma/serum of the hepatic fibrosis patient is obviously different from that in the plasma/serum of the hepatitis patient, so that the hepatic fibrosis patient and the hepatitis patient can be effectively distinguished. When the expression level of the microRNA marker reaches the liver fibrosis level, the liver cirrhosis can be diagnosed. The invention also provides a diagnostic kit for hepatic fibrosis. The hepatic fibrosis microRNA marker provided by the invention is used for guiding the diagnosis of hepatic fibrosis, and has the characteristics of simplicity in operation, safety, no wound, high sensitivity, high specificity and easiness in large-scale screening.

Description

Application of microRNA marker miR-122-5p in hepatic fibrosis diagnosis
Technical Field
The invention relates to the technical field of biomedicine, in particular to a hepatic fibrosis microRNA marker and application thereof in diagnosis of hepatic fibrosis.
Background
China is a big country with viral hepatitis, and particularly, the number of hepatitis B patients is large. Hepatitis B carriers account for approximately 8-10% of the general population, with approximately 25% developing chronic hepatitis and further developing hepatic fibrosis and cirrhosis. About 10% of the last cases developed hepatocellular carcinoma (HCC). The data show that the average medical cost of a chronic hepatitis B patient per year is about 1100 Yuan, while if the patient progresses to hepatocellular carcinoma, the average cost per year is as much as 4 million RMB. Hepatic fibrosis is a key stage in the process of chronic hepatitis-cirrhosis-liver cancer, and if hepatic fibrosis can be diagnosed at an early stage, the development of diseases can be reversed through treatment.
The hepatic fibrosis patient has no obvious symptoms, and the conventional index of blood has no obvious change. At present, no effective diagnosis means exists for the hepatic fibrosis clinically. Histopathological biopsy is the current 'gold standard' for judging the degree of liver fibrosis and cirrhosis, but the liver puncture location is single-point and limited in material collection, which is not enough to reflect the overall condition of the liver, and about 25% of patients are misdiagnosed and missed in clinic due to pathological diagnosis deviation. Fibroscan (instantaneous elastography) is based on ultrasound examination and determines liver fibrosis and cirrhosis grading by determining liver stiffness values. The detection method has the advantages of simplicity, no pain, rapidness, good patient compliance, no need of hospitalization, good repeatability, contribution to dynamic follow-up observation and the like. However, the application of Fibroscan is limited by factors such as liver inflammation condition, ascites, large blood vessels around the liver, fatty lesion, narrow intercostal space and the like. Resulting in a low diagnosis standard population rate of Fibroscan for hepatic fibrosis. In summary, clinical application of a single technique or index at present cannot accurately and timely diagnose the degree of hepatic fibrosis progression, so that hepatic fibrosis diagnosis still depends on pathological standards of liver biopsy, and a convenient, timely and noninvasive hepatic fibrosis diagnosis index is urgently needed in clinic.
microRNA (miRNA) is a research hotspot in recent years, is single-stranded small-molecule RNA widely existing in eukaryotes, has no coding function, can be combined with flanking regions of a gene sequence to inhibit translation of target mRNA, and has high conservation, time sequence and tissue specificity. At present, the kit plays an important role in the fields of clinical diagnosis, treatment, prognosis evaluation and the like of various diseases such as tumors, hematopathy, virus infection and the like. Although some research has been carried out in this field, the change of microRNA expression of hepatic fibrosis patients has not been studied deeply, and in clinical and research, there is a need to find microRNA markers that can effectively determine hepatic fibrosis, especially microRNA markers for distinguishing hepatic fibrosis from hepatitis.
Disclosure of Invention
The invention provides application of a microRNA nucleic acid molecule miR-122-5p (SEQ ID No.: 1) in preparation of a hepatic fibrosis diagnosis reagent. Preferably, said use is for differentiating between diagnosis of liver fibrosis and hepatitis.
Preferably, the diagnostic reagent determines whether hepatic fibrosis occurs by detecting the content of the hepatic fibrosis microRNA marker in the plasma/serum of a subject and comparing the level with the average level of hepatitis patients.
The method uses a quantitative PCR method or other methods to detect the hepatic fibrosis microRNA marker content in the plasma/serum of a subject.
The invention provides a hepatic fibrosis diagnosis kit in a second aspect, which comprises the following components in parts by weight: 1, specific reverse transcription primer, specific upstream primer, specific probe and qPCR detection downstream primer. Preferably, said SEQ ID No.: 1 is SEQ ID No.: 2, and/or the specific probe is SEQ ID No.: 3, and/or the specific upstream primer is SEQ ID No.: 4, and/or qPCR detection of the downstream primer as SEQ ID No.: 5.
the diagnostic kit further comprises:
(1) a reagent for extracting total RNA from blood plasma/blood serum,
(2) a reagent for reverse transcription is added into the reaction solution,
(3) and (4) quantifying PCR reagents.
Wherein the plasma/serum total RNA extraction reagent comprises an External Control sequence (External Control) with a sequence of 5'-UUUGGAUUGAAGGGAGCUCUA-3'; the reverse transcription reagent comprises a specific reverse transcription primer of a hepatic fibrosis microRNA marker; the quantitative PCR reagent comprises a specific probe and a specific forward primer of the hepatic fibrosis microRNA marker.
The hepatic fibrosis microRNA marker has the characteristics of simple operation, safety, no wound, high sensitivity, high specificity and easy mass screening.
Drawings
FIG. 1 is a graph showing ROC (receiver operating characteristic) curves in patients with liver fibrosis and hepatitis, using Spss mapping software, with true positive rate (sensitivity) as ordinate and false positive rate (1-specificity) as abscissa. The result of miR-122-5p shows that the AUC (area under the curve) reaches 0.863, which indicates that the hepatic fibrosis microRNA marker can effectively distinguish hepatic fibrosis and hepatitis patients.
Detailed Description
Micrornas or mirnas, as described herein, have their ordinary meaning in the art. That is, micrornas represent RNA molecules from genetic loci that are processed from transcripts that can form local RNA precursor microRNA structures. Mature micrornas are typically 20, 21, 22, 23, 24, or 25 nucleotides in length, although other numbers of nucleotides may be present, for example 18, 19, 26, 27, or 28 nucleotides.
According to the invention, the diagnosis of hepatitis B and hepatic fibrosis is based on the viral hepatitis prevention and treatment guidelines of the Chinese medical society of 2000, which are as follows: has a history of chronic infection of hepatitis virus, has shown hepatitis symptoms and liver function abnormality, and has been shown by imaging to locally or diffusely hepatic fibrosis, but has not shown patients with cirrhosis.
According to the invention, the hepatitis diagnosis is based on the viral hepatitis prevention and treatment guidelines of the Chinese medical society of 2000, which are as follows: the course of hepatitis is more than half a year, or the original hepatitis virus carrying history, this time, the same pathogen will again appear hepatitis symptoms, signs and liver function abnormalities, but patients without liver fibrosis/cirrhosis will be diagnosed as chronic hepatitis.
The hepatic fibrosis microRNA marker comprises a microRNA nucleic acid molecule: miR-122-5 p.
Name of microRNA MicroRNA sequence
miR-122-5p Uggagugugacaaugguguuug(SEQ ID NO.：1)
In a preferred embodiment, said one microRNA is differentially expressed in at least one target plasma/serum compared to at least one control plasma/serum. The target plasma/serum is from hepatic fibrosis patients, and the control plasma/serum is from hepatitis patients.
The inventor finds that the content of the hepatic fibrosis microRNA marker in plasma/serum of a hepatic fibrosis patient is obviously different from that of a hepatitis patient, and the hepatic fibrosis and the hepatitis can be effectively distinguished. Therefore, the expression level of the hepatic fibrosis microRNA marker is closely related to the infection of hepatitis B virus, chronic hepatitis and the development of the course of hepatic fibrosis.
On the basis of the discovery, the invention provides the application of the hepatic fibrosis microRNA marker in preparing a hepatic fibrosis diagnostic reagent.
Specifically, the diagnostic reagent diagnoses hepatic fibrosis by detecting the content of hepatic fibrosis microRNA markers in serum/plasma of a subject and comparing the hepatic fibrosis microRNA markers with the average level of hepatitis patients. Wherein, the content of the hepatic fibrosis microRNA marker in the plasma/serum of the cirrhosis patients is obviously different from that of the hepatitis patients. In a specific embodiment, the quantitative PCR method is used to detect the hepatic fibrosis microRNA marker content in the serum/plasma of the subject.
The diagnosis kit comprises specific primers/probes of the hepatic fibrosis microRNA marker. The specific primer/probe comprises: miR-122-5p specific reverse transcription primers, specific upstream primers and specific probes.
Figure BSA0000208014770000041
The diagnostic kit further comprises:
(1) a reagent for extracting total RNA from blood plasma/blood serum,
(2) a reagent for reverse transcription is added into the reaction solution,
(3) the quantitative PCR reagent is added into the reaction kettle,
wherein the plasma/serum total RNA extraction reagent comprises an External Control sequence (External Control) with a sequence of 5'-UUUGGAUUGAAGGGAGCUCUA-3', and the reverse transcription reagent comprises a specific reverse transcription primer of a hepatic fibrosis microRNA marker; the quantitative PCR reagent comprises a specific probe and a specific forward primer of the hepatic fibrosis microRNA marker.
The technical scheme of the invention is further illustrated by the specific embodiment and the attached drawings, but the technical scheme can be understood by those skilled in the art: the following detailed description and examples are intended to illustrate the invention and should not be construed as limiting the invention in any way.
Example 1 plasma sample Collection and preparation
During the period of 1-2016 12 in 2014, 27 plasma samples of patients meeting the above definition of liver fibrosis and 27 plasma samples meeting the above definition of hepatitis were collected in advance from the Beijing Youtanan hospital affiliated with the university of capital medical.
Collecting 10ml of peripheral venous blood, performing EDTA anticoagulation, and collecting plasma as follows: the whole blood sample was centrifuged at 1,500-3,000g for 15min at 4 ℃ in a centrifuge. The supernatant plasma was carefully transferred to a 1.5mL RNase-free sterile centrifuge tube using a 200. mu.L pipette gun. Each sample is marked. It is important to preserve the plasma samples in an ultra-low temperature (-80 ℃) freezer within 4 hours.
Example 2 extraction of Total RNA from plasma
Total RNA was extracted from plasma using an RNA extraction kit (Beijing, Osbeckon Biotech Co., Ltd.) and the quality of RNA extraction from plasma was monitored by adding 1. mu.l (20nM) of an External Control sequence (External Control) having a sequence of 5'-UUUGGAUUGAAGGGAGCUCUA-3' (synthesized by King-rui Biotechnology Co., Ltd.) to 250. mu.l of plasma. The concentration of extracted total RNA was determined using Thermo NanoDrop2000 c.
Example 3 quantitative determination of MicroRNA in plasma
(1) Obtaining cDNA single strand by RT-PCR:
i. mu.l of microRNA solution was taken and 1.0. mu.l (4.0. mu.M) of specific reverse transcription primer (synthesized by Shanghai Biotechnology engineering Co., Ltd.) was added thereto.
Preparing a reverse transcription reaction solution:
Figure BSA0000208014770000051
(Note: all products used were products of Beijing Kuangbo Biotech Co., Ltd.)
And iii, mixing the solutions obtained by the i and the ii, incubating at 16 ℃ for 30min, incubating at 42 ℃ for 30min, incubating at 85 ℃ for 5min, and cooling to 4 ℃ to obtain the cDNA.
iv, subpackaging the product obtained in the step iii and storing at-20 ℃.
(2) quantitative qPCR detection:
i. preparing qPCR reaction liquid:
Figure BSA0000208014770000061
(Note: Each primer/probe was synthesized by Shanghai Biotechnology, Inc., 2 XqPCR Mix and ROX were provided by Baori doctor Biotechnology (Beijing) Inc., and the remaining reagents were from Beijing Kuangbo Biotechnology, Inc.)
ii, after the prepared reaction solution is fully mixed, putting the mixture into a quantitative PCR detector (such as ABI7900), and setting the program as follows:
Figure BSA0000208014770000062
example 4: and (4) analyzing results:
and performing data analysis by adopting OmicOffcie analysis software.
Methods for RT-PCR and 2-ΔΔCThe T method is described in Kenneth J Livak et al (Analysis of a responsive expression data using a real-time quantitative PCR and the 2-ΔΔCMethods 25, 402-408(2001), which is incorporated herein by reference in its entirety.
According to the embodiment, the expression level of microRNA markers of 27 hepatic fibrosis patients and 27 hepatitis patients is tested, and the results are shown in the following table.
Detection marker DDCt P value
miR-122-5p 2.93 4.61×10-7
The results of plotting ROC (receiver operating characterization) curves using the Spss plotting software with true positive rate (sensitivity) as ordinate and false positive rate (1-specificity) as abscissa are shown in FIG. 1. The AUC (area under the curve) of the miR-122-5p reaches 0.863, which shows that the hepatic fibrosis microRNA marker can effectively distinguish hepatic fibrosis and hepatitis patients.
On the ROC curve, since the john index (sensitivity + specificity-1) is the largest when Ct is 22.246, Ct is 22.246 as the cutoff value determined as a result. Namely:
when the Ct of the sample is more than or equal to 22.246, the sample is judged to be a hepatic fibrosis patient sample;
when the Ct of the sample is less than 22.246, the sample is judged to be a hepatitis patient sample.
According to the above determination method, the expression levels of miR-122-5p in the plasma of 27 patients with liver fibrosis and 27 patients with hepatitis are detected, and whether the subjects are patients with liver fibrosis or hepatitis B is predicted according to the miRNA expression levels. The results of the blind tests are shown in Table 2 below.
TABLE 2
Hepatic fibrosis Hepatitis (HAV)
Number of samples 27 27
Results 22 23
Prediction accuracy 81.48％ 85.19％

Claims (7)

  1. Use of microRNA nucleic acid molecule miR-122-5p (SEQ ID NO.: 1) in preparation of a hepatic fibrosis diagnosis reagent.
  2. 2. The use of claim 1, wherein the diagnostic reagent is used to determine whether liver fibrosis is occurring by detecting the amount of the hepatic fibrosis microRNA marker in the plasma/serum of the subject and comparing the detected level with the average level of hepatitis patients.
  3. 3. The use of claim 2, wherein quantitative PCR or other methods are used to detect the level of hepatic fibrosis microRNA markers in the plasma/serum of the subject.
  4. 4. Use according to any one of claims 1 to 3, for distinguishing between a diagnosis of liver fibrosis and hepatitis.
  5. 5. A hepatic fibrosis diagnostic kit is characterized in that: the kit comprises SEQ ID No.: 1, specific reverse transcription primer, specific upstream primer, specific probe and qPCR detection downstream primer.
  6. 6. The diagnostic kit of claim 5, further comprising:
    (1) a reagent for extracting total RNA from blood plasma/blood serum,
    (2) a reagent for reverse transcription is added into the reaction solution,
    (3) and (4) quantifying PCR reagents.
  7. 7. The diagnostic kit of claim 6, wherein said sequence of SEQ ID No.: 1 is SEQ ID No.: 2, and/or the specific probe is SEQ ID No.: 3, and/or the specific upstream primer is SEQ ID No.: 4, and/or qPCR detection of the downstream primer as SEQ ID No.: 5.
CN202010375751.7A 2019-04-19 2020-04-19 Application of microRNA marker miR-122-5p in hepatic fibrosis diagnosis Pending CN111826434A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910316960 2019-04-19
CN2019103169601 2019-04-19

Publications (1)

Publication Number Publication Date
CN111826434A true CN111826434A (en) 2020-10-27

Family

ID=72914045

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010375751.7A Pending CN111826434A (en) 2019-04-19 2020-04-19 Application of microRNA marker miR-122-5p in hepatic fibrosis diagnosis

Country Status (1)

Country Link
CN (1) CN111826434A (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112795636A (en) * 2021-01-07 2021-05-14 成都医学院 Application of reagent for detecting miR-122 in liver tissue in preparation of liver cirrhosis screening kit
CN114134223A (en) * 2021-12-02 2022-03-04 青岛市中心血站 Blood detection kit for hepatitis C virus-related liver fibrosis

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043114A1 (en) * 2008-10-13 2010-04-22 北京命码生科科技有限公司 Use of serum/plasma microrna in early diagnosis of hbv infection and liver cancer
JP2012125215A (en) * 2010-12-17 2012-07-05 Osaka City Univ Method for determining presence and/or severity of hepatic fibrosis, determining marker and kit used for determination, and method for predicting therapeutic effect of hepatic fibrosis, effect prediction marker, and kit used for effect prediction
CN106337051A (en) * 2015-07-09 2017-01-18 首都医科大学附属北京佑安医院 Hepatitis b/hepatic cirrhosis microRNA molecular marker combination and purpose thereof
CN106337050A (en) * 2015-07-09 2017-01-18 首都医科大学附属北京佑安医院 Liver cirrhosis micro RNA molecular marker, and applications thereof
US20190004066A1 (en) * 2017-06-13 2019-01-03 Gilead Sciences, Inc. Methods of treating liver fibrosis

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010043114A1 (en) * 2008-10-13 2010-04-22 北京命码生科科技有限公司 Use of serum/plasma microrna in early diagnosis of hbv infection and liver cancer
JP2012125215A (en) * 2010-12-17 2012-07-05 Osaka City Univ Method for determining presence and/or severity of hepatic fibrosis, determining marker and kit used for determination, and method for predicting therapeutic effect of hepatic fibrosis, effect prediction marker, and kit used for effect prediction
CN106337051A (en) * 2015-07-09 2017-01-18 首都医科大学附属北京佑安医院 Hepatitis b/hepatic cirrhosis microRNA molecular marker combination and purpose thereof
CN106337050A (en) * 2015-07-09 2017-01-18 首都医科大学附属北京佑安医院 Liver cirrhosis micro RNA molecular marker, and applications thereof
US20190004066A1 (en) * 2017-06-13 2019-01-03 Gilead Sciences, Inc. Methods of treating liver fibrosis

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
TIE-ZHENG WANG ET AL.: "Plasma microRNA: A novel non-invasive biomarker for HBV-associated liver fibrosis staging", 《EXPERIMENTAL AND THERAPEUTIC MEDICINE》 *
中华医学会传染病与寄生虫病学分会肝病学分会: "病毒性肝炎防治方案", 《中华肝脏病杂志》 *
刘顺: "荧光定量PCR检测血清miR-122在肝纤维化相关疾病中表达水平的研究", 《中国优秀博硕士学位论文全文数据库(硕士)医药卫生科技辑》 *
李萍英等: "microRNA在慢性乙型肝炎肝纤维化中的诊断价值", 《临床肝胆病杂志》 *
林勇等: "慢性乙型肝炎肝纤维化评估中血清miR-122的临床意义", 《福建医药杂志》 *
汤纳平等: "血清miR-122作为药物肝损伤生物标志物的敏感性和特异性比较", 《中国药理学与毒理学杂志》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112795636A (en) * 2021-01-07 2021-05-14 成都医学院 Application of reagent for detecting miR-122 in liver tissue in preparation of liver cirrhosis screening kit
CN114134223A (en) * 2021-12-02 2022-03-04 青岛市中心血站 Blood detection kit for hepatitis C virus-related liver fibrosis
CN114134223B (en) * 2021-12-02 2022-10-11 青岛市中心血站 Blood detection kit for hepatitis C virus-related liver fibrosis

Similar Documents

Publication Publication Date Title
CN105671181B (en) Gene marker, primer, probe and kit for detecting lung cancer
CN110484624B (en) Gastric cancer biomarker based on peripheral blood and detection method and application thereof
CN107779504B (en) MicroRNA molecular marker for colorectal cancer and application thereof
CN111826434A (en) Application of microRNA marker miR-122-5p in hepatic fibrosis diagnosis
CN108949961A (en) For detecting kit and its screening of adenovirus pneumonia
KR20130029079A (en) Marker consisting of plasma microrna and a new method for diagnosis of hepatocellular carcinoma
CN111733227B (en) Molecular marker circRNA for diagnosing idiopathic optic neuritis, kit and application
KR20220052461A (en) MicroRNA-1246 for diagnosing of ovarian cancer and use thereof
CN109536502B (en) PCR (polymerase chain reaction) internal reference applicable to plasma exosome miRNA of patient with gestational trophoblastic tumor
CN115772524A (en) Marker combination and application thereof in preparation of reagent for diagnosing thyroid cancer
CN115851958A (en) Primer, probe, kit and method for detecting pancreatic cancer related gene methylation
CN112391478B (en) Application of exosome mRNA in diagnosis of breast diseases
TWI758670B (en) Health risk assessment method
CN112501294B (en) Colorectal cancer biomarker and application thereof
CN109182514B (en) Lung cancer diagnosis or metastasis diagnosis marker LncRNA Loc729658 and kit and application thereof
CN113718028A (en) micro-RNA based preeclampsia diagnostic application and composition
CN116218980A (en) microRNA molecular marker combination for hepatitis B cirrhosis and application thereof
CN116218981A (en) Hepatitis B liver fibrosis microRNA molecular marker combination and application thereof
CN112111570A (en) Serum miRNA marker related to auxiliary diagnosis of ischemic stroke and application thereof
CN117448442A (en) 3 '-end 2' -O-methylation modified micro ribonucleic acid combination for detecting atherosclerosis cardiovascular diseases and application thereof
US11427870B2 (en) Method for treating encapsulating peritoneal sclerosis
LU503615B1 (en) Serodiagnosis marker for gastric cancer (gc), and determination method
AU2021105761A4 (en) Use of microRNA markers microRNA-130a and microRNA-130b in diagnosis of Hepatic fibrosis
CN116497112A (en) Detection product, primer or combination thereof, detection product and application
CN109868319B (en) MicroRNA molecular marker for screening saliva of acute altitude stress susceptible and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20201224

Address after: 100176 3rd floor, building 2, aipuyi building, No.1, Disheng East Road, Beijing Yizhuang Economic and Technological Development Zone, Daxing District, Beijing

Applicant after: Beijing Guangbo star Biotechnology Co.,Ltd.

Address before: 100176 3rd floor, building 2, aipuyi building, No.1, Disheng East Road, Yizhuang Economic and Technological Development Zone, Daxing District, Beijing

Applicant before: BEIJING QUANTOBIO BIOTECHNOLOGY Co.,Ltd.

TA01 Transfer of patent application right
RJ01 Rejection of invention patent application after publication

Application publication date: 20201027

RJ01 Rejection of invention patent application after publication